Company intelligence / Profile preview

Genvace Biotechnology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Genvace Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to create treatments for infectious diseases and various forms of cancer. Its lead program is an mRNA vaccine candidate targeting COVID-19, which has progressed into clinical trials. Genvace aims to establish a comprehensive ecosystem for mRNA drug discovery, including sequence optimization and large-scale manufacturing capabilities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Beyond the preview

Go deeper on Genvace Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genvace Biotechnology.

Explore the full profile